ZTSZoetis Inc.

$52B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.6B+7.1% YoY

Gross Profit

$981M62.7% margin

Operating Income

$436M27.9% margin

Net Income

$345M22.1% margin

EPS (Diluted)

$0.71

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

$584M

Free Cash Flow

$446M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$10.8B

Total Liabilities

$8.6B

Stockholders' Equity

$2.2B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.5B	+7.1%
Gross Profit	$981M	$980M	+0.1%
Operating Income	$436M	$509M	-14.3%
Net Income	$345M	$81M	+325.9%

Revenue Segments

Horses

$2.3B73%

Cattle

$525M16%

Swine

$163M5%

Poultry

$127M4%

Fish

$40M1%

Geographic Segments

United States Segment

$1.5B100%

ZTS Q4 2018 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena